VANCOUVER, BC, November 23rd 2023 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB)(OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that a Failure to File Cease TradeOrder (“FFCTO”) issued October 5th, 2023, by the Ontario Securities Commission has beenr evoked as of November 22, 2023, and Canadian trading in BioVaxys stock (CSE:BIOV) will resume. The FFCTO was issued following the Company’s delay in filing the periodic disclosure of its financial statement and analysis for the quarter ending July 31, 2023 to the Canadian regulatory authorities; all disclosure documents for that quarter have been submitted.In other news, The Company’s US Patent Application #18/557,655 entitled BIHAPTENIZEDAUTOLOGOUS VACCINES AND USES THEREOF was submitted October 27th, 2023, with the UnitedStates patent & Trademark Office (“USPTO”). This application was filed as a US national stage of the previously filed International Application. BioVaxys is continuing additional national phase filings for its bihaptenized vaccine platform outside the US, with additional submissions upcoming.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceutical companybased in Vancouver, Canada, is developing BVX-0918, a personalizedimmunotherapeutic vaccine using our proprietary HapTenix© 'neoantigen' tumor cellconstruct platform for treating refractive late stage ovarian cancer, and is also theexclusive US distributor of a portfolio of OTC female reproductive health productscurrently marketed in the EU from Barcelona-based Procare Health Iberia. BioVaxysis also exploring vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccinebased on its HapTenix©platform through academic and other collaborations.ON BEHALF OF THE BOARDSigned “James Passin”James Passin, CEO+1 646 452 7054Cautionary Statements Regarding Forward Looking InformationThis press release includes certain “forward-looking information” and“forward-looking statements” (collectively “forward-looking statements”)within the meaning of applicable Canadian and United States securitieslegislation including the United States Private Securities Litigation ReformAct of 1995. All statements, other than statements of historical fact, includedherein, without limitation, statements relating the future operating orfinancial performance of the Company, are forward looking statements.Forward-looking statements are frequently, but not always, identified bywords such as “expects”, “anticipates”, “believes”, “intends”, “estimates”,“potential”, “possible”, and similar expressions, or statements that events,conditions, or results “will”, “may”, “could”, or “should” occur or beachieved.. There can be no assurance that such statements will prove tobe accurate, and actual results and future events could differ materiallyfrom those expressed or implied in such forward-looking statements.These forward-looking statements reflect the beliefs, opinions andprojections on the date the statements are made and are based upon anumber of assumptions and estimates, primarily the assumption thatBioVaxys will be successful in developing and testing vaccines, that, whileconsidered reasonable by the Company, are inherently subject to significantbusiness, economic, competitive, political and social uncertainties andcontingencies including, primarily but without limitation, the risk thatBioVaxys’ vaccines will not prove to be effective and/ or will not receive therequired regulatory approvals. With regards to BioVaxys’ business, there area number of risks that could affect the development of its biotechnologyproducts, including, without limitation, the need for additional capital tofund clinical trials, its lack of operating history, uncertainty about whether itsproducts will complete the long, complex and expensive clinical trial andregulatory approval process for approval of new drugs necessary formarketing approval, uncertainty about whether its autologous cell vaccineimmunotherapy can be developed to produce safe and effective productsand, if so, whether its vaccine products will be commercially accepted andprofitable, the expenses, delays and uncertainties and complicationstypically encountered by development stage biopharmaceutical businesses,financial and development obligations under license arrangements in orderto protect its rights to its products and technologies, obtaining andprotecting new intellectual property rights and avoiding infringement tothird parties and their dependence on manufacturing by third parties.The Company does not assume any obligation to update the forwardlooking statements of beliefs, opinions, projections, or other factors, shouldthey change, except as required by law.
Revolutionizing treatment delivery